AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 240,421 shares of the company's stock, valued at approximately $1,375,000. AWM Investment Company Inc. owned about 1.28% of OptimizeRx as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company's stock valued at $1,362,000 after acquiring an additional 187,278 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of OptimizeRx during the 1st quarter worth approximately $1,185,000. Next Century Growth Investors LLC increased its stake in shares of OptimizeRx by 139.8% during the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company's stock worth $6,196,000 after purchasing an additional 294,688 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company's stock worth $3,540,000 after purchasing an additional 102,661 shares during the period. Finally, Hillsdale Investment Management Inc. raised its holdings in shares of OptimizeRx by 10.9% in the 4th quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company's stock worth $249,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 76.47% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Wall Street Zen lowered shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. Citigroup restated a "market outperform" rating on shares of OptimizeRx in a research note on Friday, August 14th. Citizens Jmp raised their price objective on shares of OptimizeRx from $9.00 to $11.00 and gave the stock a "market outperform" rating in a report on Friday, August 14th. B. Riley Financial reduced their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 13th. Finally, Stephens dropped their target price on OptimizeRx from $10.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, OptimizeRx currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.43.
Get Our Latest Report on OptimizeRx
OptimizeRx Stock Up 2.7%
Shares of NASDAQ OPRX opened at $7.86 on Wednesday. OptimizeRx Corp. has a one year low of $4.54 and a one year high of $22.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58. The firm's 50 day simple moving average is $6.50 and its two-hundred day simple moving average is $6.55. The stock has a market capitalization of $148.08 million, a P/E ratio of 34.18 and a beta of 1.08.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%.The firm had revenue of $20.50 million for the quarter, compared to analysts' expectations of $20.20 million. As a group, analysts expect that OptimizeRx Corp. will post 0.51 EPS for the current fiscal year.
About OptimizeRx
(
Free Report)
OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.
The company's core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
